Simon Lowth-is acting CEO since June 1,2012.He was CFO of AZN since 2007.Before that he had was Exec.Director of Scottish Power-where he headed Corporate Strategy and Development for 2 years .He has 15 years experience with Mckinsey.He did a good job for Scottish Power.
But Pascal Soriot--is far better-worked at Genentech which was bought by Roche.Genentech is a great Bio-Tech co.from Palo Alto. I had a meeting with Genentech in 1980--Great researchers.At that time they had hired a CEO from Abbott--and they had a drug that dissolved BLOOD CLOT fast.It used to cost 1000 to 2000$ per dose--given when heart attack patient arrived within 3 hours.
Please type in Http://www. as Yahoo messaging does not allow URL's any more for Amarin.
You meant the CEO, who was just appointed. Acting CEO was the former CFO.
Pascal Soriot is probably French/Swiss. Last job, Roche COO. Before that Head of commercial operations and head of strategic mktg at Roche. He also spent a short time as COO as San Francisco based Genentech (which Roache owns). So he knows the U.S.
Roche is an aggressive acquirer. He must have been involved with all the Roche deals.
When it comes to AMRN, AZN has already done the work. He can just put his signature or say no.